Glucose Metabolism Disease
Glucose metabolism disease refers to a group of conditions characterized by impaired regulation of glucose (sugar) levels in the body. These diseases arise from dysfunctions in how the body produces, utilizes, or stores glucose, a primary energy source. Conditions such as type 2 diabetes are prominent examples within this category, significantly impacting health and quality of life globally.
The biological basisof glucose metabolism diseases involves complex interactions between genetic predispositions and environmental factors. Normally, the hormone insulin, produced by the pancreas, plays a crucial role in regulating blood glucose by facilitating its uptake into cells for energy or storage. In glucose metabolism diseases, this process can be disrupted through various mechanisms, including insulin resistance (where cells do not respond effectively to insulin) or insufficient insulin production by the pancreas. Research, particularly through genome-wide association studies (GWAS), has identified numerous genetic variants that influence glucose metabolism. For instance, variations in genes likeMTNR1Bhave been found to influence fasting glucose levels[1], and the G6PC2/ABCB11 genomic region has also been associated with these levels [2]. These genetic insights contribute to understanding the complex genetic architecture underlying such conditions [3].
Clinical relevanceof glucose metabolism diseases is profound, as uncontrolled high blood glucose levels can lead to a range of severe health complications affecting the heart, kidneys, eyes, and nerves. Early detection and management, often involving monitoring fasting glucose levels and lifestyle modifications, are critical for preventing or delaying these complications. Advances in genetic research offer the potential for more personalized risk assessments and targeted interventions.
The social importanceof addressing glucose metabolism diseases is immense. Type 2 diabetes, a major glucose metabolism disorder, is a global health concern, “spreading worldwide and exerting a fearsome human and economic toll”[3]. It contributes significantly to morbidity and mortality, placing a substantial burden on healthcare systems and economies worldwide. A better understanding of the basic molecular causes, including genetic factors, is essential for developing effective prevention strategies and improved treatments[3].
Limitations
Section titled “Limitations”Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”The interpretation of genetic associations with glucose metabolism diseases is influenced by inherent study design and statistical limitations. Initial genome-wide association studies (GWAS) often require extensive replication to confirm findings, as even statistically significant associations may not consistently hold across diverse cohorts The development of T2D is influenced by both genetic predispositions and environmental factors, with intensive lifestyle modifications proven to significantly reduce its incidence.[2]
A fundamental conceptual framework for understanding these disorders is insulin resistance, which is described as a multifaceted syndrome contributing to conditions such as non-insulin-dependent diabetes mellitus (NIDDM, an earlier term for T2D), obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.[4]The term “glycemia” refers to the presence of glucose in the blood, and research indicates that metabolic risk factors continuously worsen across the entire spectrum of nondiabetic glucose tolerance, suggesting a continuum of risk rather than distinct categorical states.[5]
Classification Systems and Disease Subtypes
Section titled “Classification Systems and Disease Subtypes”Glucose metabolism diseases are broadly categorized into distinct types, with Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D) being the most common. T1D is typically identified by an age of diagnosis below 17 years and a requirement for insulin dependence for at least six months following diagnosis.[6]Diagnostic criteria for excluding autoimmune diabetes, a hallmark of T1D, include the absence of first-degree relatives with T1D and a significant interval of at least one year between initial diagnosis and the commencement of regular insulin therapy.[6]
Beyond the common forms, specific rare monogenic disorders are recognized, such as Maturity Onset Diabetes of the Young (MODY), Permanent Neonatal Diabetes (PNDM), and mitochondrial diabetes. These distinct subtypes are typically excluded from studies focusing on the more prevalent diabetes types through the application of standard clinical criteria based on an individual’s personal and family medical history. [6]Furthermore, the nosology of diabetes considers its association with broader conditions like the metabolic syndrome, which links insulin resistance with a cluster of factors including obesity, hypertension, dyslipidemia, and an elevated risk of cardiovascular events.[7]
Diagnostic and Measurement Criteria
Section titled “Diagnostic and Measurement Criteria”The diagnosis of diabetes is typically established either by current prescribed treatment with various antidiabetic agents, such as sulphonylureas, biguanides, other oral medications, or insulin, or through laboratory evidence of hyperglycemia.[6] Specific cut-off values for hyperglycemia include a fasting blood sugar of ≥126 mg/dL or a random blood sugar of ≥200 mg/dL. [8] These diagnostic criteria are often standardized according to guidelines from organizations such as the World Health Organization. [6]
Key quantitative traits measured to assess glucose metabolism include fasting plasma glucose and insulin concentrations.[2]Tools like the Homeostasis Model Assessment (HOMA) provide an operational definition for estimating insulin resistance and beta-cell function from these fasting measurements.[9]Other measures, such as the insulin sensitivity index are also employed to quantify insulin resistance, which can serve as a predictor for the development of type 2 diabetes.[8]For accurate research analyses, blood samples for glucose and insulin measurements typically require individuals to be fasting, and those who are diabetic, on diabetic medication, or pregnant are often excluded from specific analyses.[10]
Signs and Symptoms
Section titled “Signs and Symptoms”Clinical Manifestations and Key Biochemical Markers
Section titled “Clinical Manifestations and Key Biochemical Markers”Glucose metabolism diseases are characterized by alterations in blood glucose levels, which can manifest through a range of clinical presentations, from asymptomatic elevations detected during screening to overt symptoms of hyperglycemia. Key objective measures for assessing glucose metabolism include fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c), both considered primary diabetes-related quantitative traits[3]. FPG levels are notably influenced by genetic variants, such as those in the MTNR1B gene and the G6PC2/ABCB11 genomic region [1]. These biochemical markers are crucial for identifying individuals at risk or with established disease, and changes in plasma glucose levels can indicate the progression towards type 2 diabetes, often characterized by moderate then rapid increases[11].
The assessment of glucose metabolism relies heavily on these measurable biomarkers. Fasting plasma glucose can be measured at specific clinical examinations, and for a more comprehensive view, time-averaged FPG (tFPG) levels can be derived from multiple serial examinations over time[3]. Similarly, HbA1c provides an average blood glucose level over the preceding months, offering a valuable long-term indicator of glycemic control[3]. These objective measurements are fundamental for diagnosing glucose metabolism disease and are frequently utilized in studies, including those involving non-diabetic subjects, to understand underlying metabolic traits and identify risk factors[2].
Phenotypic Variability and Associated Conditions
Section titled “Phenotypic Variability and Associated Conditions”The presentation of glucose metabolism disease exhibits significant inter-individual variation and phenotypic diversity, influenced by a complex interplay of genetic predispositions and environmental factors. Genetic variants, such as those found inMTNR1B and the G6PC2/ABCB11region, are known to influence fasting glucose levels, contributing to the heterogeneity observed in patient populations[1]. This variability is also evident in disease progression, where individuals may experience different patterns of glucose elevation, including coordinate changes in plasma glucose and pancreatic β-cell function in those at high risk for type 2 diabetes[12].
Glucose metabolism diseases, particularly type 2 diabetes, often present as part of a broader, multifaceted syndrome encompassing insulin resistance, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease[2]. This clustering of conditions underscores the systemic nature of metabolic dysfunction. Age-related changes can also influence glucose metabolism, with the risk of type 2 diabetes increasing significantly with age[3]. The diverse clinical phenotypes and severity ranges observed necessitate a comprehensive approach to diagnosis and management, considering both genetic and lifestyle influences[13].
Diagnostic Significance and Prognostic Indicators
Section titled “Diagnostic Significance and Prognostic Indicators”The consistent monitoring of key biomarkers like fasting plasma glucose and HbA1c holds significant diagnostic value, enabling the early identification of impaired glucose tolerance or established type 2 diabetes[3]. Early diagnosis is critical as interventions, such as lifestyle changes or pharmaceutical agents like metformin, have been shown to reduce the incidence of type 2 diabetes in at-risk populations[13]. These objective measures serve as essential diagnostic tools and provide red flags for clinicians to initiate preventive or therapeutic strategies.
Beyond diagnosis, these markers also function as important prognostic indicators, helping to predict disease progression and risk. Sustained increases in fasting glucose, even if moderate initially, are characteristic of the progression towards type 2 diabetes[11]. Furthermore, genome-wide association studies have identified various susceptibility loci for type 2 diabetes, enhancing the understanding of genetic architecture and potentially improving risk prediction and prognostic assessment [14]. The correlation of these genetic insights with clinical measures allows for a more personalized approach to patient care and disease management.
Causes of Glucose Metabolism Disease
Section titled “Causes of Glucose Metabolism Disease”Glucose metabolism diseases, such as type 2 diabetes, arise from a complex interplay of genetic predispositions, environmental factors, and physiological dysregulations. Understanding these multifaceted causes is crucial for prevention and management.
Genetic Predisposition and Complex Inheritance
Section titled “Genetic Predisposition and Complex Inheritance”Glucose metabolism disorders, particularly type 2 diabetes (T2DM), have a substantial genetic basis, with the heritability of fasting glucose concentrations estimated to range from 25% to 40%[15]. The genetic architecture of these conditions is complex and heterogeneous, typically involving numerous genes, each contributing a relatively modest effect to the overall risk [3]. Genome-wide association studies (GWAS) have been instrumental in identifying multiple susceptibility loci for T2DM, including 16 novel loci and additional ones through meta-analyses [15]. Specific genetic variations in regions like MTNR1B and the G6PC2/ABCB11genomic region have been identified as influencing fasting glucose levels, underscoring the role of inherited variants in the regulation of metabolic processes[1].
Environmental and Lifestyle Factors
Section titled “Environmental and Lifestyle Factors”Environmental factors significantly contribute to the development of glucose metabolism disorders. Lifestyle choices, especially dietary patterns and physical activity, are critical determinants of disease risk[15]. Compelling evidence from large-scale intervention trials, such as the Diabetes Prevention Program and the Finnish Diabetes Prevention Study, has demonstrated that intensive lifestyle modifications can substantially reduce the incidence of type 2 diabetes[13]. These findings highlight how external exposures and daily habits directly influence the pathophysiology of glucose dysregulation.
Gene-Environment Interactions
Section titled “Gene-Environment Interactions”The emergence of glucose metabolism diseases frequently stems from intricate interactions between an individual’s genetic predispositions and their environmental exposures. While inherited genetic factors confer a baseline susceptibility, environmental triggers often play a critical role in determining when and how the condition manifests[16]. For example, individuals with a genetic susceptibility to type 2 diabetes can significantly lower their risk through targeted lifestyle interventions, demonstrating that modifying environmental factors can effectively mitigate genetic predispositions[15]. This dynamic interplay illustrates that the full impact of specific genetic variants may only become apparent under particular environmental conditions.
Physiological Dysregulation and Comorbidities
Section titled “Physiological Dysregulation and Comorbidities”Glucose metabolism diseases are characterized by pervasive physiological dysfunctions affecting multiple organs and tissues, including the pancreas, skeletal muscle, liver, adipose tissue, and the vascular system[3]. This widespread organ involvement contributes to the diverse clinical presentations observed in affected individuals. Moreover, conditions like insulin resistance are recognized as multifaceted syndromes that encompass a cluster of interrelated health problems, such as obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease[17]. These comorbidities not only frequently coexist but also exacerbate the underlying glucose dysregulation, thereby contributing to the progression and increased severity of the metabolic disorder.
Biological Background
Section titled “Biological Background”Glucose Homeostasis and Energy Regulation
Section titled “Glucose Homeostasis and Energy Regulation”Glucose serves as the primary energy source for the human body, with its levels tightly controlled through a delicate balance of absorption from the gut, production predominantly by the liver, and utilization by various tissues, including those sensitive and insensitive to insulin[2]. This intricate homeostatic control ensures a constant supply of energy while preventing harmful fluctuations in blood glucose. The gut plays a crucial role in absorbing dietary glucose, which is then processed and stored or released by the liver to meet the body’s immediate energy demands. Cellular functions across all tissues depend on this regulated glucose supply for metabolic processes.
Hormonal and Neural Regulation of Glucose Levels
Section titled “Hormonal and Neural Regulation of Glucose Levels”Maintaining stable glucose levels involves complex interactions between humoral (hormonal) and neural mechanisms. Key biomolecules, such as hormones like insulin, act as critical regulators, signaling to target tissues to facilitate glucose uptake and storage or to inhibit glucose production. Receptors on cell surfaces detect these hormonal signals, initiating intracellular signaling pathways that modulate metabolic enzyme activity and gene expression patterns. This intricate regulatory network ensures that glucose production and utilization are precisely balanced to sustain normal physiological functions.
Genetic Influences on Glucose Metabolism
Section titled “Genetic Influences on Glucose Metabolism”Genetic mechanisms play a significant role in determining an individual’s glucose metabolism profile and susceptibility to related diseases. Specific gene functions, influenced by genetic variants, can alter the efficiency of glucose regulation. For instance, variations within theMTNR1Bgene have been identified to influence fasting glucose levels, indicating its role in glucose homeostasis[1]. Similarly, variations in the G6PC2/ABCB11genomic region are also associated with fasting glucose levels, highlighting the importance of these specific loci in metabolic control[2]. These genetic differences can impact the expression of critical proteins and enzymes involved in glucose transport, synthesis, or breakdown, thereby affecting overall metabolic health and contributing to the genetic architecture of complex conditions like type 2 diabetes[18].
Pathophysiology of Dysregulated Glucose Metabolism and Disease
Section titled “Pathophysiology of Dysregulated Glucose Metabolism and Disease”Disruptions in the tightly regulated glucose homeostatic processes underlie the pathophysiology of various metabolic diseases, most notably type 2 diabetes. When the balance between glucose production and utilization is disturbed, either through impaired insulin action, insufficient insulin production, or excessive glucose output, it leads to chronically elevated blood glucose levels. These homeostatic disruptions can trigger compensatory responses in the body, such as increased insulin secretion, but over time, these mechanisms may fail, leading to progressive cellular dysfunction. The systemic consequences of prolonged glucose dysregulation are far-reaching, affecting multiple organs and tissues and contributing to a range of complications associated with metabolic diseases.
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Regulation of Glucose Homeostasis and Core Metabolism
Section titled “Regulation of Glucose Homeostasis and Core Metabolism”Glucose serves as the primary energy source for human physiological processes, with its levels tightly controlled through a dynamic balance of absorption, production, and utilization[2]. Following digestion, glucose is absorbed via the gut and distributed throughout the body. The liver plays a critical role in glucose production, primarily through glycogenolysis and gluconeogenesis, while various insulin-sensitive and insulin-insensitive tissues consume glucose for energy or storage[2]. This intricate metabolic equilibrium, essential for energy metabolism, is maintained through complex interactions involving both humoral (hormonal) and neural mechanisms that precisely regulate metabolic flux and ensure stable glucose levels[2].
Genetic Modulators of Glucose Levels and Gene Regulation
Section titled “Genetic Modulators of Glucose Levels and Gene Regulation”Genetic factors significantly influence an individual’s fasting glucose levels, highlighting the role of gene regulation in metabolic control. Variations identified within the G6PC2/ABCB11 genomic region have been associated with alterations in fasting glucose[2]. Similarly, variants in the MTNR1B gene also influence fasting glucose levels[1]. These genetic changes likely impact the expression or function of proteins crucial for glucose metabolism, thereby modifying metabolic pathways and contributing to individual differences in glucose regulation.
Interconnected Signaling Networks and Cellular Responses
Section titled “Interconnected Signaling Networks and Cellular Responses”The homeostatic control of glucose involves elaborate signaling pathways that integrate systemic information and orchestrate cellular responses. Humoral and neural mechanisms, described as complex interacting systems, regulate the balance between glucose production and utilization[2]. These networks typically involve receptor activation, triggering intracellular signaling cascades that lead to the regulation of transcription factors. These transcription factors, in turn, control the expression of genes involved in glucose metabolism, while intricate feedback loops ensure continuous adjustment and maintenance of glucose balance across various tissues and organs.
Dysregulation and Pathogenesis of Glucose Metabolism Diseases
Section titled “Dysregulation and Pathogenesis of Glucose Metabolism Diseases”When the finely tuned balance of glucose homeostasis is disrupted, it can lead to pathway dysregulation, manifesting as glucose metabolism diseases such as type 2 diabetes. Genetic predispositions, including identified susceptibility loci for type 2 diabetes, highlight specific vulnerabilities within the metabolic and signaling networks[1]. Dysregulation can arise from impairments in glucose absorption, excessive production, or insufficient utilization, often involving a breakdown in the signaling pathways that normally coordinate these processes. Understanding these specific points of dysregulation, and the failure of any compensatory mechanisms, is critical for identifying potential therapeutic targets aimed at restoring metabolic balance and mitigating disease progression.
Clinical Relevance
Section titled “Clinical Relevance”Genetic Risk Assessment and Early Intervention
Section titled “Genetic Risk Assessment and Early Intervention”The understanding of genetic factors significantly enhances the ability to assess an individual’s risk for glucose metabolism disorders, such as type 2 diabetes, even prior to the onset of clinical symptoms. Genome-wide association studies have identified specific genetic variants, including those in theMTNR1B and G6PC2/ABCB11genomic regions, that influence fasting glucose levels[1] [2]. These discoveries provide new insights into the genetic architecture underlying type 2 diabetes susceptibility [2] [18]. Given that fasting glucose concentrations are notably heritable, with estimates ranging from 25% to 40%[2] [8], incorporating this genetic information allows for improved risk stratification, enabling the identification of high-risk individuals.
This enhanced risk assessment facilitates personalized prevention strategies. For individuals identified as genetically predisposed, early interventions focusing on intensive lifestyle modifications have demonstrated significant reductions in the incidence of type 2 diabetes[2]. Combining genetic insights with an understanding of environmental contributions supports a proactive approach to managing glucose metabolism, moving towards personalized medicine where preventative measures are tailored to an individual’s unique genetic and lifestyle profile.
Prognostic Value and Disease Trajectory Prediction
Section titled “Prognostic Value and Disease Trajectory Prediction”Genetic insights into glucose metabolism disorders offer valuable prognostic information, aiding in the prediction of disease progression, potential outcomes, and long-term implications for patient health. While individual genetic variants may not always provide clinically useful prediction on their own, their evaluation in combination can contribute to a more comprehensive understanding of a patient’s disease trajectory[6]. For instance, specific genetic profiles might indicate a higher likelihood of developing complications or a particular response to therapeutic interventions, allowing clinicians to anticipate needs and tailor monitoring strategies accordingly.
The prognostic utility extends to predicting morbidity-free survival, particularly concerning conditions frequently associated with glucose metabolism disorders, such as cardiovascular disease (CVD)[8]. Integrating genetic data can help identify individuals at higher risk for adverse long-term outcomes, prompting earlier or more intensive management strategies to improve patient quality of life and extend healthy lifespan. This predictive capability supports the development of more effective and individualized treatment and monitoring protocols.
Comorbidities and Integrated Patient Management
Section titled “Comorbidities and Integrated Patient Management”Glucose metabolism disorders are frequently associated with a spectrum of comorbidities, and genetic studies illuminate the underlying connections between these conditions. There is a recognized association between glucose metabolism diseases and cardiovascular conditions, such as coronary artery disease (CAD)[19] [20], with genetic analyses revealing shared susceptibility loci that contribute to overlapping phenotypes [18]. Understanding this shared genetic architecture is crucial for managing the complex interplay of these diseases, as it suggests common biological pathways and predispositions.
This comprehensive perspective on comorbidities informs an integrated approach to patient care. By recognizing the genetic predispositions to related conditions, clinicians can implement broader screening, prevention, and treatment strategies that address the full scope of a patient’s health rather than focusing solely on the glucose disorder[8]. This approach aligns with personalized medicine, where genetic insights guide holistic management plans, optimizing outcomes by considering both the primary disease and its associated complications, thereby improving the overall effectiveness of patient interventions.
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs560887 | G6PC2, SPC25 | coronary artery calcification blood glucose amount HOMA-B glucose measurement metabolite measurement |
| rs1799884 rs741037 | GCK | blood glucose amount HbA1c measurement type 2 diabetes mellitus metabolic syndrome glucose measurement |
| rs10830963 | MTNR1B | blood glucose amount HOMA-B metabolite measurement type 2 diabetes mellitus insulin measurement |
| rs10258074 | GTF3AP5 - AGMO | glucose metabolism disease |
| rs1337918 | FOXA2 - LNCNEF | glucose measurement glucose metabolism disease |
| rs17476364 | HK1 | erythrocyte volume hematocrit reticulocyte count hemoglobin measurement Red cell distribution width |
| rs144440467 | NKX2-1-AS1 | glucose metabolism disease |
Frequently Asked Questions About Glucose_Metabolism_Disease
Section titled “Frequently Asked Questions About Glucose_Metabolism_Disease”These questions address the most important and specific aspects of glucose_metabolism_disease based on current genetic research.
1. Why do I struggle with my sugar levels, but my friend eats anything?
Section titled “1. Why do I struggle with my sugar levels, but my friend eats anything?”Your ability to process sugar is a complex interplay of your genetic makeup and lifestyle. While your friend might have genetic variations that make them more efficient at handling glucose, you might have different predispositions, such as genes influencing fasting glucose levels likeMTNR1B or the G6PC2/ABCB11 region. This means that even with similar diets, your bodies can respond very differently due to underlying biological differences.
2. My parents have sugar problems; will I definitely get them too?
Section titled “2. My parents have sugar problems; will I definitely get them too?”Not necessarily, but your risk is higher. Glucose metabolism diseases have a strong genetic component, meaning you inherit predispositions from your parents. However, environmental factors like diet, exercise, and lifestyle also play a crucial role, so you can significantly influence your outcome through proactive management.
3. Can I just exercise away my family’s history of sugar issues?
Section titled “3. Can I just exercise away my family’s history of sugar issues?”Exercise is incredibly beneficial and a key part of managing your risk, but it’s often not a complete “fix” if you have a strong genetic predisposition. While lifestyle changes can help overcome or delay the onset of conditions like insulin resistance, your inherited genetic architecture still influences how your body processes glucose. It’s about combining genetic awareness with healthy habits for the best outcome.
4. Does my stress at work make my sugar levels worse?
Section titled “4. Does my stress at work make my sugar levels worse?”Yes, stress can definitely impact your sugar levels. While the article focuses on genetics, it acknowledges the interplay with environmental factors. Chronic stress can influence hormone levels that affect glucose metabolism, potentially exacerbating issues like insulin resistance or making it harder for your body to regulate blood sugar effectively.
5. What does my fasting sugar level actually tell me?
Section titled “5. What does my fasting sugar level actually tell me?”Your fasting sugar level is a critical indicator of how well your body is regulating glucose when you haven’t eaten for a while. It’s a key measurement for detecting glucose metabolism diseases early and is used to monitor the effectiveness of management strategies. Consistent high fasting levels can signal issues like insulin resistance or insufficient insulin production.
6. Could a genetic test tell me my personal sugar risk?
Section titled “6. Could a genetic test tell me my personal sugar risk?”Genetic tests are becoming more advanced and can identify variations in genes associated with glucose metabolism, like those found through genome-wide association studies (GWAS) such asMTNR1B. While these tests can provide insights into your genetic predisposition, they don’t give a complete picture. Many genetic factors are still unknown, and lifestyle plays a huge role in your overall risk.
7. I’m from a certain background; does that increase my risk for sugar problems?
Section titled “7. I’m from a certain background; does that increase my risk for sugar problems?”Yes, your ancestral background can influence your risk. Genetic studies have found that the prevalence and specific genetic risk factors for glucose metabolism diseases can vary across different ethnic groups. Research often highlights limitations in generalizability, meaning findings from one population (e.g., European) might not fully apply to others, indicating unique genetic influences in diverse populations.
8. Why do some people never seem to get sugar problems, no matter what?
Section titled “8. Why do some people never seem to get sugar problems, no matter what?”Some individuals are genetically predisposed to have more efficient glucose metabolism, making them less susceptible to sugar problems even with less-than-ideal lifestyles. Their genes might allow for better insulin sensitivity or more robust insulin production, offering a protective effect compared to those with genetic variations that increase risk.
9. Is it true my sugar metabolism slows down as I get older?
Section titled “9. Is it true my sugar metabolism slows down as I get older?”While the article doesn’t directly state that metabolism “slows down” with age, it highlights that glucose metabolism diseases are a global health concern impacting health and quality of life. Age is generally a risk factor for many chronic conditions, and the cumulative effect of genetic predispositions and environmental exposures over time can certainly make glucose regulation more challenging as you age.
10. Why does managing my sugar feel so complicated?
Section titled “10. Why does managing my sugar feel so complicated?”Managing glucose metabolism diseases is complex because it involves intricate biological processes influenced by many factors. Your body’s glucose regulation is a dynamic system involving insulin production, cellular response, and genetic predispositions, all interacting with your diet, activity, and environment. This complexity means that effective management often requires a multi-faceted approach personalized to your unique situation.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
Section titled “References”[1] Prokopenko I et al. “Variants in MTNR1B influence fasting glucose levels.”Nat Genet, 2008.
[2] Chen WM et al. “Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels.”J Clin Invest, 2008.
[3] Meigs JB et al. “Genome-wide association with diabetes-related traits in the Framingham Heart Study.” BMC Med Genet, 2007.
[4] DeFronzo RA, Ferrannini E. “Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.”Diabetes Care, 1991.
[5] Meigs JB et al. “Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study.”Annals of Internal Medicine, 1998.
[6] Wellcome Trust Case Control Consortium. “Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.” Nature, 2007.
[7] Rutter MK et al. “Insulin Resistance, the Metabolic Syndrome, and Incident Cardiovascular Events in The Framingham Offspring Study.”Diabetes, 2005.
[8] Lunetta KL et al. “Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study.” BMC Med Genet, 2007.
[9] Matthews DR et al. “Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.”Diabetologia, 1985.
[10] Sabatti C et al. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”Nat Genet, 2008.
[11] Mason, C.C., Hanson, R.L., and Knowler, W.C. “Progression to type 2 diabetes characterized by moderate then rapid glucose increases.”Diabetes, vol. 56, no. 8, 2007, pp. 2054-2061.
[12] Xiang, Anny H. et al. “Coordinate changes in plasma glucose and pancreatic β-cell function in Latino women at high risk for type 2 diabetes.”Diabetes, vol. 55, no. 4, 2006, pp. 1074-1079.
[13] Diabetes Prevention Program Research Group. “Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin.”N. Engl. J. Med., vol. 346, 2002, pp. 393–403.
[14] Zeggini, E. et al. “Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes.” Nature Genetics, vol. 40, no. 5, 2008, pp. 638-645.
[15] Chen, W. M., et al. “Variations in the G6PC2/ABCB11 Genomic Region Are Associated with Fasting Glucose Levels.”J Clin Invest.
[16] Rich, S. S. “Mapping Genes in Diabetes.” Diabetes, vol. 39, 1990, pp. 1315–1319.
[17] Reaven, G. M. “Banting Lecture 1988. Role of Insulin Resistance in Human Disease.”Diabetes, vol. 37, 1991, pp. 1595–1607.
[18] Barrett, J. C., et al. “Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease.”Nat Genet, 2008.
[19] Samani, N. J., et al. “Genomewide association analysis of coronary artery disease.”New England Journal of Medicine, 2007.
[20] Erdmann, J., et al. “New susceptibility locus for coronary artery disease on chromosome 3q22.3.”Nature Genetics, 2009.
[21] Burgner, D. et al. “A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease.”PLoS Genet, vol. 5, no. 1, 2009, p. e1000319.
[22] Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, et al. “Genome-wide association analysis identifies loci for type 2 diabetes.” Nature, vol. 445, no. 7130, 2007, pp. 881-885.
[23] Garcia-Barcelo, M. M., et al. “Genome-wide association study identifies NRG1 as a susceptibility locus for Hirschsprung’s disease.”Proc Natl Acad Sci U S A, 2009.
[24] Ghosh, S., and Schork, N. J. “Genetic Analysis of NIDDM: The Study of Quantitative Traits.” Diabetes, 1996.
[25] Gutt M et al. “Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures.”Diabetes Res Clin Pract, 2000.
[26] Hanley AJ et al. “Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study.”Diabetes, 2003.
[27] Prokopenko, I, et al. “Variants in MTNR1B influence fasting glucose levels.”Nat Genet, vol. 41, no. 1, 2009, PMID: 19060907.
[28] Sabatti, C, et al. “Genome-wide Association Analysis of Metabolic Traits in a Birth Cohort from a Founder Population.”Nat Genet, vol. 41, no. 1, 2009, pp. 153-61.
[29] Tuomilehto, J., et al. “Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle Among Subjects with Impaired Glucose Tolerance.”N. Engl. J. Med., vol. 344, 2001, pp. 1343–1350.